Valneva saw the highest growth of 1.99% in patent filings in April and 3.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 1.99% and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of Valneva‘s patent filings and grants. Buy the databook here.
Valneva has been focused on protecting inventions in United States(US) with six publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 50% filings and 57% grants. The United States(US), European Patent Office(EPO), Denmark(DK), and Spain(ES) patent Office are among the top ten patent offices where Valneva is filings its patents. Among the top granted patent authorities, Valneva has 57% of its grants in United States(US), 14% in European Patent Office(EPO) and 14% in Spain(ES).
Chinese Academy of Sciences and Roche could be the strongest competitors for Valneva
Patents related to climate change and genomics lead Valneva's portfolio
Valneva has the highest number of patents in climate change followed by, genomics and rare diseases. For climate change, nearly 60% of patents were filed and 56% of patents were granted in Q2 2024.
Dengue fever related patents lead Valneva portfolio followed by yellow fever, and zika virus infections
Valneva has highest number of patents in dengue fever followed by yellow fever, zika virus infections, japanese encephalitis, and chikungunya fever. For dengue fever, nearly 20% of patents were filed and 14% of patents were granted in Q2 2024.
For comprehensive analysis of Valneva's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.